Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 03 Feb 2026 | Carmen Laplaza Santos Head of Unit | Exchange of views on the competitiveness of the European pharmaceutical sector. | — |
| 03 Feb 2026 | Carmen Laplaza Santos Head of Unit | Exchange of views on the competitiveness of the European pharmaceutical sector. | SRC |
| 01 Dec 2025 | Jana Dabbelt Cabinet member | Digital and AI as an enabler in healthcare | — |
| 01 Dec 2025 | Jana Dabbelt Cabinet member | Digital and AI as an enabler in healthcare | SRC |
| 11 Sept 2025 | Olivér Várhelyi Commissioner | Consumer protection dimension of specific dossiers | SRC |
| 11 Sept 2025 | Olivér Várhelyi Commissioner | Consumer protection dimension of specific dossiers | — |
| 23 May 2025 | Jan Hoogmartens Cabinet member | Working visit to GSK vaccine production site. | — |
| 23 May 2025 | Hadja Lahbib Commissioner | Working visit to GSK vaccine production site. | SRC |
| 23 May 2025 | Jan Hoogmartens Cabinet member | Working visit to GSK vaccine production site. | SRC |
| 23 May 2025 | Florika Fink-Hooijer Director-General | Working visit to GSK vaccine production site | SRC |
| 23 May 2025 | Florika Fink-Hooijer Director-General | Working visit to GSK vaccine production site | — |
| 10 Oct 2024 | Peter Van Kemseke Cabinet member | EB Summit | SRC |
| 10 Oct 2024 | Peter Van Kemseke Cabinet member | EB Summit | — |
| 28 Apr 2021 | Maurits-Jan Prinz Cabinet member | EU vaccine production and pandemic preparedness | — |
| 28 Apr 2021 | Maurits-Jan Prinz Cabinet member | EU vaccine production and pandemic preparedness | SRC |
| 11 Feb 2021 | Sandra Gallina Director-General | vaccines | — |
| 11 Feb 2021 | Sandra Gallina Director-General | vaccines | SRC |
| 31 May 2018 | Annika Nowak Cabinet member | Brexit preparedness | — |
| 31 May 2018 | Annika Nowak Cabinet member | Brexit preparedness | SRC |
| 23 Mar 2018 | Leila Fernandez-Stembridge Cabinet member | IP regime generic manufacturers in the pharmaceutical industry | SRC |
| 23 Mar 2018 | Leila Fernandez-Stembridge Cabinet member | IP regime generic manufacturers in the pharmaceutical industry | — |
| 01 Dec 2017 | Nele Eichhorn Cabinet member | FTA implementation & transparency / trade relations with China, Turkey, Russia / importance of including vaccines in trade negotiations | — |
| 01 Dec 2017 | Nele Eichhorn Cabinet member | FTA implementation & transparency / trade relations with China, Turkey, Russia / importance of including vaccines in trade negotiations | SRC |
| 09 Nov 2017 | Marika Lautso-Mousnier Cabinet member | Innovation in the pharmaceutical sector, SPC, health technology assessments | — |
| 09 Nov 2017 | Marika Lautso-Mousnier Cabinet member | Innovation in the pharmaceutical sector, SPC, health technology assessments | SRC |
Mission & Goals
GSK is a global biopharmaceutical company with the purpose to unite science, technology, and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people over the next 10 years. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance. We are a company where outstanding people can thrive. We prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We will focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology. Our scale and strong R&D and manufacturing footprint in the EU give us a unique opportunity to make a positive impact on the lives of people in the region.
EU Legislative Interests
Revision EU Pharmaceutical legislation, European Health Data Space Regulation, EU AI Act, Urban Waste Water Treatment Directive, F-Gas Regulation, Vaccination Policy, R&D policy / IHI, Antimicrobial resistance, HERA and Biopreparedness, EU Trade, Biotech Act, Critical Medicines Act
Communication Activities
Mainly via participation in events organized by think tanks and trade associations we are members of (EFPIA, Vaccines Europe, British Chamber of Commerce EU & Belgium, American Chamber of Commerce to the European Union , Friends of Europe, European Roundtable for Industry)
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
American Chamber of Commerce to the European Union (AmChamEU) European Federation of Pharmaceutical Industries and Associations (EFPIA) Vaccines Europe (VE) International Pharmaceutical Aerosol Consortium (IPAC) Digital Europe MedTech Europe European Policy Centre (EPC) Friends of Europe European Roundtable for Industry (ERT) British Chamber of Commerce EU & Belgium
Organisation Members
N/A
Additional Information
GSK is following the Transparency Register Code of Conduct and Implementing Guidelines. The organisation is also following the EFPIA Codes. The amount declared in answer (c) includes: relevant percentage of trade associations' work as declared, consultants as declared, percentage of employees and their salaries whose activities are considered in-scope.
Connected Legislation